EGFR Mutated EGFR TKI Naive Metastatic NSCLC
1 clinical trials · Condition
◉ Watch EGFR Mutated EGFR TKI Naive Metastatic NSCLC
| Record | Firm | Date |
|---|---|---|
| Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT02206763) | Sierra Oncology LLC - a GSK company | 2014-10-16 |
Track EGFR Mutated EGFR TKI Naive Metastatic NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.